RefleXion Medical
- 17/11/2023
- Unknown
- $105,000,000
SCINTIX biology-guided radiotherapy now FDA cleared.
SCINTIX™ therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
- Industry Medical Equipment Manufacturing
- Website https://reflexion.com/
- LinkedIn https://www.linkedin.com/company/reflexion-medical/about/
Related People
Todd PowellFounder
Todd has over 25 years of experience in medical-technology & innovation leadership with multi-national, teams of all sizes from startups to over 1200 employees. IPO experience along with numerous mergers, acquisitions, technology and commercial partnerships.
He has a particular ability to formulate and nurture a vision and the strategy to commercially realize it through thoughtfully developed, cross-functional teams at the highest organizational levels.
Through his experience and industry relationships, Todd has a deep understanding of the complexities and nuance of the oncology market including the rapidly changing clinical, financial and operational challenges within healthcare networks.
With a pragmatic and direct leadership style, Todd authentically communicates complex situations and opportunities in a trust-building manner to employees, the marketplace and investment communities as well as board directors.